IP Library Granted Patent US 7,635,577
Granted Patent B2
US 7,635,577 · App. 10/482,926 · Granted Dec 22, 2009

Process for producing human thrombin by gene modification technique

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,635,577
App. No.
10/482,926
Granted
Dec 22, 2009
Kind
B2
Abstract

A genetic recombinant human thrombin is provided. Human thrombin is efficiently prepared by the genetic engineering technique comprising the steps: (1) culturing a transfectant animal cell transfected with an expression vector in which a gene encoding human prethrombin is incorporated to the downstream of a promoter so as to produce and accumulate prethrombin in culture supernatant and recovering the produced human prethrombin; (2) treating a solution containing human prethrombin recovered in step (1) with ecarin so as to convert human prethrombin into human thrombin; and (3) purifying the solution obtained after the above activation process to obtain purified human thrombin. The present invention allows for provision of human thrombin in a large scale in a safe and economical manner due to exclusion of blood-derived components.

Claims (10)

1. A process for preparing human α-thrombin by a genetic engineering technique which comprises the following steps:

(1) culturing a transfectant animal cell transfected with an expression vector in which a DNA encoding human prethrombin-2 with an upstream prothrombin preproleader sequence is incorporated to the downstream of a chicken β-actin promoter so as to produce and accumulate human prethrombin-2 at a high expression level of at least 90 μ/ml in culture supernatant and recovering the produced human prethrombin-2, wherein said DNA encoding human prethrombin-2 with an upstream preproleader sequence has the nucleotide sequence as set forth in SEQ ID NO:11;

(2) treating a solution containing human prethrombin recovered in step (1) with ecarin so as to convert human prethrombin into human α-thrombin in a solution; and

(3) purifying the solution obtained after the treatment in step (2) to obtain purified human α-thrombin.

2. The process for preparing the human α-thrombin of claim 1 , wherein said expression vector further contains an amplification sequence and the transfectant is cultured under conditions suitable for DNA amplification.

3. The process for preparing the human α-thrombin of claim 2 , wherein said amplification sequence is a DNA encoding dihydrofolate reductase.

4. The process for preparing the human α-thrombin of claim 1 , wherein said transfectant is an animal cell selected from the group consisting of Chinese hamster ovary cell (CHO cell), mouse myeloma cell, BHK21 cell, 293 cell and COS cell.

5. The process for preparing the human α-thrombin of claim 1 , wherein said ecarin used to convert human prethrombin-2 is prepared by a genetic engineering technique.

6. The process for preparing the human α-thrombin of claim 1 , wherein said purifying of human α-thrombin consists of affinity chromatography with hirudin peptide.

7. The process for preparing the human α-thrombin of claim 1 , wherein said transfectant is an animal cell selected from the group consisting of Chinese hamster ovary cell (CHO cell), mouse myeloma cell, BHK21 cell, 293 cell and COS cell.

Assignments (2)
CHANGE OF NAME Recorded Jan 16, 2013
From: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 029636/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2004
From: YONEMURA, HIROSHI; IMAMURA, TAKAYUKI; NAKATAKE, HIROSHI; SOEJIMA, KENJI; NOZAKI, CHIKATERU
To: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 015587/0988 →